EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
Non-small cell lung cancer (NSCLC) typically presents in patients at an advanced stage, with a poor prognosis. The development of epidermal growth factor receptor (EGFR) – tyrosine kinase inhibitors (TKIs) and the systematic identification of EGFR mutations heralded the advent of targeted therapy i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital
2021-03-01
|
| Series: | Jurnal Penyakit Dalam Indonesia |
| Subjects: | |
| Online Access: | http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/166/266 |
| Summary: | Non-small cell lung cancer (NSCLC) typically presents in patients at an advanced stage, with a poor prognosis. The development of epidermal growth factor receptor (EGFR) – tyrosine kinase inhibitors (TKIs) and the systematic identification of EGFR mutations heralded the advent of targeted therapy in lung cancer, transforming the landscape of its treatment and prognosis. This is a case of 37 years-old female patient presented with metastatic bone disease secondary to pulmonary adenocarcinoma EGFR mutation positive which demonstrated a remarkable result to TKI. |
|---|---|
| ISSN: | 2406-8969 2549-0621 |